Drug intelligence / Profile preview

Hawthorn Mingzi

Development stage: Preclinical
Administration: Oral

Overview

Hawthorn Mingzi is a traditional Chinese medicine compound, often prepared as a solid drink, that combines hawthorn (Crataegus) and cassia seed (决明子, Jue Ming Zi). It is investigated for its potential to manage dyslipidemia, likely through mechanisms related to lipid metabolism and cardiovascular health. Both ingredients have a long history of use in traditional medicine for their beneficial effects on cardiovascular health and lipid profiles.

Other names: Hawthorn Mingzi Solid Drink山楂明子固体饮料

Targets

SOAT1 (Sterol O-acyltransferase)PPARA (Peroxisome proliferator-activated receptor alpha)LDLR (Low-density lipoprotein receptor)LPL (Lipoprotein lipase)

Beyond the preview

Go deeper on Hawthorn Mingzi.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hawthorn Mingzi.

Explore the full profile